NASDAQ$IBRX

ImmunityBio Inc · Q2 2019 earnings

Q2 2019 earnings · · Investor relations

Headline financials

Total Revenue

$17K

Previous: $4K+325.0%
EPS (adj)

-$0.17

Previous: -$0.35+51.4%
Capital Expenditures

-$3.09M

Previous: -$7.39M+58.2%
Free Cash Flow

-$19.8M

Previous: -$35.1M+43.7%
Net Income

-$16.7M

Previous: -$27.7M+39.8%
Operating Income

-$17.3M

Previous: -$28.3M+38.8%
Gross Profit

$17K

Previous: $4K+325.0%
R&D Expense

$13.1M

Previous: $14.7M-10.6%

Revenue & EPS history

ImmunityBio · Revenue · Quarterly

$17K

Q2 2019+325%vs Q2 2018

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2019

Historical avgQ2 2019

-0.5%

Avg return

Earnings day

-0.4%

Avg return

5 days after

-1.9%

Avg return

30 days after

49%

21 / 43 earnings

Positive

+40.4%

Q3 2018

Best reaction

-63.3%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-7.5%-3.2%-17.5%
Q4 2025+13.2%+12.4%-7.2%
Q3 2025+3.4%+3.8%+10.1%
Q1 2025+6.4%+20.3%+35.2%
Q4 2024+6.0%+5.3%+4.2%
Q3 2024-11.4%-17.6%-44.2%
Q2 2024-17.2%-11.7%-20.3%
Q1 2024+2.5%+6.1%-23.0%
Q4 2023+14.5%+16.1%-6.1%
Q3 2023-9.3%+5.8%+0.0%
Q2 2023-9.7%-1.1%-29.2%
Q1 2023-63.3%-46.8%-54.3%
Q4 2022-16.8%-27.9%-25.4%
Q3 2022+7.4%+26.3%+26.3%
Q2 2022-3.3%+0.7%+0.4%
Q1 2022-19.3%+5.1%+16.6%
Q4 2021-4.6%-9.8%-11.3%
Q3 2021-8.7%-10.9%-24.9%
Q2 2021-0.1%-10.8%-12.2%
Q4 2020+14.7%-4.2%-12.3%
Q1 2021+14.7%+10.4%+5.0%
Q3 2020-3.5%-0.7%+26.6%
Q2 2020+7.2%-11.4%-39.0%
Q1 2020+17.5%+3.0%+46.8%
Q4 2019+16.4%+5.4%+21.8%
Q3 2019+2.8%+3.7%+38.9%
Q2 2019+8.3%+13.3%+4.2%
Q1 2019-7.3%-12.2%-15.4%
Q4 2018+1.7%+2.5%+16.8%
Q3 2018+40.4%-10.9%-41.9%
Q2 2018-7.8%-1.3%+2.2%
Q1 2018+0.5%+4.6%-4.3%
Q4 2017-6.5%-10.7%-17.8%
Q3 2017-5.7%-2.8%+17.3%
Q2 2017+5.4%-0.5%+5.8%
Q1 2017+5.5%+35.8%+49.5%
Q4 2016-2.0%-0.3%-3.7%
Q3 2016+2.2%+1.2%-12.8%
Q2 2016-2.2%-3.1%+20.6%
Q1 2016+1.8%
Q4 2015-3.3%
Q3 2015-3.5%
Q2 2015-1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro